Bluejay Diagnostics Inc

Bluejay Diagnostics enrolls 624 of 750 SYMON‑II trial patients, advancing the Symphony IL‑6 sepsis test toward regulatory approval and improved critical‑care outcomes.

Bluejay Diagnostics Inc. is a resilient player in the healthcare sector, specializing in medical diagnostics and poised to leverage its expertise to address emerging health challenges.

Bluejay Diagnostics Inc. has secured $3.7 million in funding through a warrant inducement transaction, providing the company with crucial resources to support its operations and growth initiatives.